Skip to main content
Clinical Trials/NCT03023098
NCT03023098
Completed
Not Applicable

Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study

Helsinki University Central Hospital1 site in 1 country57 target enrollmentJanuary 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peripheral Artery Occlusive Disease
Sponsor
Helsinki University Central Hospital
Enrollment
57
Locations
1
Primary Endpoint
TLR (Target lesion revascularization)
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in bypass vein grafts.

Detailed Description

Drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. Stenosis and restenosis is a known problem in bypass vein grafts, and drug-eluting devices might be beneficial in this field as well. In the procedure a conventional balloon is passed through the stenosis which is then dilated. After this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon. The stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. Follow-up will end at 12 months.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
November 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maarit Venermo

Professor of Vascular Surgery

Helsinki University Central Hospital

Eligibility Criteria

Inclusion Criteria

  • Any venous bypass with stenosis warranting intervention

Exclusion Criteria

  • Previous PTA with drug-eluting balloon, thrombolysis, coagulopathy

Outcomes

Primary Outcomes

TLR (Target lesion revascularization)

Time Frame: 12 months

Any reintervention to the same lesion.

Graft occlusion

Time Frame: 0-12 months

Occlusion of the bypass graft

Secondary Outcomes

  • Major amputation(0-12 months)
  • Death(0-12 months)

Study Sites (1)

Loading locations...

Similar Trials